# Propanc Biopharma Inc. (PPCB)

Source: https://www.quantisnow.com/company/PPCB
Generated: 2026-11-07T18:30:45.189Z

- Ticker: PPCB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001517681

## Latest PPCB news and filings

- 2026-11-02 13:30 UTC [Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer](https://www.quantisnow.com/insight/propanc-biopharma-reports-preclinical-data-with-prp-prp-plus-tgf--6766333)
- 2026-10-30 12:30 UTC [Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients](https://www.quantisnow.com/insight/propanc-biopharma-advances-bioanalytical-immunogenicity-assay-development-for-phase-1b-6764677)
- 2026-10-29 21:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-propanc-biopharma-inc-6763996)
- 2026-10-28 12:30 UTC [Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients](https://www.quantisnow.com/insight/propanc-biopharma-advances-clinical-development-preparation-for-prp-phase-1b-6760657)
- 2026-10-26 12:30 UTC [Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability](https://www.quantisnow.com/insight/propanc-biopharma-publishes-new-data-prp-reprograms-chemotherapy-resistant-pancreatic-cancer-6757138)
- 2026-10-22 20:24 UTC [CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans](https://www.quantisnow.com/insight/correction----propanc-biopharma-implements-reverse-stock-split-to-support-6755277)
- 2026-10-22 12:30 UTC [Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans](https://www.quantisnow.com/insight/propanc-biopharma-implements-reverse-stock-split-to-support-continued-nasdaq-6754560)
- 2026-10-21 13:23 UTC [SEC Form DEF 14C filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14c-filed-by-propanc-biopharma-inc-6753193)
- 2026-10-16 12:36 UTC [Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells](https://www.quantisnow.com/insight/propanc-biopharmas-lead-asset-prp-reprograms-chemotherapy-resistant-pancreatic-cancer-cells-6748765)
- 2026-10-14 12:30 UTC [Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer](https://www.quantisnow.com/insight/propanc-biopharma-announces-publication-of-pilot-study-demonstrating-potent-anti-tumor-6746000)
- 2026-10-08 21:25 UTC [SEC Form PRE 14C filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-pre-14c-filed-by-propanc-biopharma-inc-6742091)
- 2026-10-07 12:30 UTC [Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib](https://www.quantisnow.com/insight/propanc-biopharma-reports-data-showing-90-tumor-growth-inhibition-with-6739803)
- 2026-10-05 21:15 UTC [SEC Form S-1] [SEC Form S-1 filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-propanc-biopharma-inc-6737498)
- 2026-09-29 12:30 UTC [Public Offering] [Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results](https://www.quantisnow.com/insight/propanc-biopharma-provides-corporate-update-year-end-june-30-2025-26-financial-6728650)
- 2026-09-25 21:08 UTC [SEC Form 10-K] [SEC Form 10-K filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-propanc-biopharma-inc-6726717)
- 2026-09-22 12:30 UTC [Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015](https://www.quantisnow.com/insight/propanc-biopharma-highlights-differentiated-prp-pancreatic-cancer-data-versus-emerging-6722518)
- 2026-09-16 12:30 UTC [Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.](https://www.quantisnow.com/insight/propanc-biopharma-positions-prps-emt-reversal-mechanism-as-a-complementary-backbone-6717037)
- 2026-09-09 12:30 UTC [Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027](https://www.quantisnow.com/insight/propanc-biopharma-to-initiate-world-first-phase-1b-first-in-human-study-of-6709416)
- 2026-08-27 12:30 UTC [Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit](https://www.quantisnow.com/insight/propanc-biopharma-announces-compelling-new-preclinical-pancreatic-cancer-data-for-6696516)
- 2026-08-18 12:30 UTC [Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP](https://www.quantisnow.com/insight/propanc-biopharma-clears-path-for-world-first-phase-1b-clinical-study-6685999)
- 2026-08-12 12:30 UTC [Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers](https://www.quantisnow.com/insight/propanc-biopharma-highlights-differentiated-proenzyme-therapy-prp-as-a-potential-6677159)
- 2026-08-06 12:30 UTC [Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models](https://www.quantisnow.com/insight/propanc-biopharma-announces-positive-preclinical-and-early-translational-data-for-6667637)
- 2026-08-05 12:30 UTC [Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program](https://www.quantisnow.com/insight/propanc-biopharma-completes-first-tranche-of-50-million-share-repurchase-6664173)
- 2026-07-28 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-propanc-biopharma-inc-6650392)
- 2026-07-17 21:30 UTC [SEC Form S-1] [SEC Form S-1 filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-propanc-biopharma-inc-6641478)
- 2026-07-14 20:01 UTC [SEC Form 8-K] [Propanc Biopharma Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/propanc-biopharma-inc-filed-sec-form-8-k-financial-statements-and-6636664)
- 2026-07-02 12:30 UTC [Propanc Biopharma Initiates $5.0 Million Share Repurchase Program](https://www.quantisnow.com/insight/propanc-biopharma-initiates-50-million-share-repurchase-program-6624321)
- 2026-06-16 12:45 UTC [Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study](https://www.quantisnow.com/insight/propanc-biopharmas-ceo-tours-european-cdmo-plans-for-gmp-production-6604108)
- 2026-06-11 14:44 UTC [ShareStructure.io Announces Investor Education Platform on Public Company Financing Activity.](https://www.quantisnow.com/insight/sharestructureio-announces-investor-education-platform-on-public-company-financing-activity-6598550)
- 2026-06-11 12:30 UTC [Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program](https://www.quantisnow.com/insight/propanc-biopharma-authorizes-50-million-share-repurchase-program-6598339)
- 2026-06-02 09:30 UTC [Propanc Biopharma's CEO Attends Keynote Address, "Rejuvenation and Health: Science for an Ageing Society," at the University of Granada, Spain](https://www.quantisnow.com/insight/propanc-biopharmas-ceo-attends-keynote-address-rejuvenation-and-health-science-6582881)
- 2026-05-20 12:45 UTC [Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade](https://www.quantisnow.com/insight/propanc-biopharmas-ceo-forecasts-new-medical-breakthroughs-in-the-fight-6564497)
- 2026-05-19 12:45 UTC [Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients](https://www.quantisnow.com/insight/propanc-biopharma-engages-european-cdmo-for-gmp-production-of-prp-6561890)
- 2026-05-15 12:45 UTC [Dividends] [Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results](https://www.quantisnow.com/insight/propanc-biopharma-provides-corporate-update-and-reports-third-quarter-202526-6556015)
- 2026-05-14 21:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-propanc-biopharma-inc-6554926)
- 2026-05-14 02:00 UTC [Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans](https://www.quantisnow.com/insight/propanc-biopharma-implements-reverse-stock-split-to-support-continued-nasdaq-6552034)
- 2026-04-21 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-propanc-biopharma-inc-6507405)
- 2026-04-10 21:29 UTC [SEC Form S-1] [SEC Form S-1 filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-propanc-biopharma-inc-6496715)
- 2026-03-31 10:12 UTC [SEC Form DEF 14C filed by Propanc Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14c-filed-by-propanc-biopharma-inc-6477688)
- 2026-03-24 12:45 UTC [Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain](https://www.quantisnow.com/insight/propanc-biopharma-executes-multi-yr-anti-aging-cancer-research-collaboration-with-the-6466364)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PPCB
- Earnings history: https://www.quantisnow.com/earnings/PPCB
- Dividend history: https://www.quantisnow.com/dividends/PPCB
- Insider transactions: https://www.quantisnow.com/insiders/PPCB
- Options chain: https://www.quantisnow.com/options/PPCB
- SEC 8-K filings only: https://www.quantisnow.com/company/PPCB/8-k
- RSS and alerts for PPCB: https://www.quantisnow.com/docs/rss-feeds.md